Abstract
Successful treatment of Type 1 diabetes (T1D) requires precise insulin dosing and reliable ways of glycemia monitoring. Self-monitoring of bloodglucose (SMBG), Flash glucose monitoring (FGM) and continuous glucose monitoring (CGM) can be used for day-to-day monitoring.
The basis of CGM and FGM is glycemic sensor inserted into the subcutaneous tissue. CGM automatically informs the patient about glucose development atapproximately five-minute intervals.
With FGM, the patient is informed only after placing the receiver in close proximity to the sensor. The accuracyof both CGM and FGM measurements has improved significantly and has been comparable in recent years to the accuracy of high qualityglucometers.
Improved sensor quality makes CGM and FGM independent of glucometers, and means CGM accuracy is no longer an obstacle toconstructing a closed loop system. So far, the major obstacle to the widespread use of CGM and FGM is the higher cost.
The following text providesan overview of the findings on CGM and FGM in patients with T1D, both of which can be expected to be widely adopted in the near future.